THRD vs. VERA, MIRM, ZLAB, VRNA, AKRO, HRMY, LGND, KROS, GPCR, and GLPG
Should you be buying TF Financial stock or one of its competitors? The main competitors of TF Financial include Vera Therapeutics (VERA), Mirum Pharmaceuticals (MIRM), Zai Lab (ZLAB), Verona Pharma (VRNA), Akero Therapeutics (AKRO), Harmony Biosciences (HRMY), Ligand Pharmaceuticals (LGND), Keros Therapeutics (KROS), Structure Therapeutics (GPCR), and Galapagos (GLPG). These companies are all part of the "pharmaceutical preparations" industry.
Vera Therapeutics (NASDAQ:VERA) and TF Financial (NASDAQ:THRD) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings, community ranking and dividends.
In the previous week, Vera Therapeutics and Vera Therapeutics both had 3 articles in the media. TF Financial's average media sentiment score of 0.80 beat Vera Therapeutics' score of 0.00 indicating that Vera Therapeutics is being referred to more favorably in the media.
Vera Therapeutics has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, TF Financial has a beta of 2.89, suggesting that its stock price is 189% more volatile than the S&P 500.
99.2% of Vera Therapeutics shares are held by institutional investors. Comparatively, 94.0% of TF Financial shares are held by institutional investors. 21.7% of Vera Therapeutics shares are held by insiders. Comparatively, 5.9% of TF Financial shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
TF Financial is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.
Vera Therapeutics currently has a consensus price target of $42.86, suggesting a potential upside of 16.78%. TF Financial has a consensus price target of $16.00, suggesting a potential upside of 28.51%. Given Vera Therapeutics' higher probable upside, analysts plainly believe TF Financial is more favorable than Vera Therapeutics.
TF Financial received 35 more outperform votes than Vera Therapeutics when rated by MarketBeat users. Likewise, 67.42% of users gave TF Financial an outperform vote while only 55.56% of users gave Vera Therapeutics an outperform vote.
Vera Therapeutics' return on equity of -5.88% beat TF Financial's return on equity.
Summary
TF Financial beats Vera Therapeutics on 8 of the 15 factors compared between the two stocks.
Get TF Financial News Delivered to You Automatically
Sign up to receive the latest news and ratings for THRD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding THRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TF Financial Competitors List
Related Companies and Tools
